EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design

Sarah E Hoffe iD, Todd A Aguilera, Parag J Parikh, Maged M Ghaly, Joseph M Herman, Joseph M Caster, Dae Won Kim, James Costello, Mokenge P Malafa, Elizabeth C Moser, Eugene P Kennedy, Kara Terry und 1 weitere

Future Oncology · 2024

DOI: 10.2217/fon-2022-1219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Sarah E Hoffe und 12 weiteren Autor:innen. Beteiligte Einrichtung: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Radiosurgery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Galera Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ablative doses of stereotactic body radiotherapy (SBRT) may improve pancreatic cancer outcomes but may carry greater potential for gastrointestinal toxicity. Rucosopasem, an investigational selective dismutase mimetic that converts superoxide to hydrogen peroxide, can potentially increase tumor control of SBRT without compromising safety. GRECO-2 is a phase II, multicenter, randomized, double-blind, placebo-controlled trial of rucosopasem in combination with SBRT in locally advanced or borderline resectable pancreatic cancer. Patients will be randomized to rucosopasem 100 mg or placebo via intravenous infusion over 15 min, before each SBRT fraction (5 × 10 Gy). The primary end point is overall survival. Secondary end points include progression-free survival, locoregional control, time to metastasis, surgical resection rate, best overall response, in-field local response and acute and long-term toxicity. The use of high doses of radiation delivered directly to tumors (stereotactic body radiation therapy [SBRT]) may improve survival compared with lower doses of radiation in patients with pancreatic cancer, but it may increase side effects. Rucosopasem, an investigational new drug being developed, can potentially improve the ability of SBRT to treat tumors without decreasing safety. In a previous study, median overall survival was improved when patients were treated with SBRT plus avasopasem, a drug that works the same way as rucosopasem. GRECO-2 is a clinical trial of rucosopasem used in combination with SBRT for treatment of localized pancreatic cancer. Patients will be randomly selected to receive either rucosopasem 100 mg or placebo via intravenous infusion over 15 min, before each SBRT treatment. The main result being studied is overall survival. Additional results include amount of time before tumors start to grow, how often patients get tumors surgically removed, best overall response and long-term safety. Clinical Trial Registration: NCT04698915 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaPancreatic NeoplasmsRadiosurgeryHumansClinical Trials, Phase II as TopicDose Fractionation, RadiationMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

pancreatic cancerrucosopasemstereotactic body radiation therapysuperoxide dismutase mimetic

Autor:innen und Institutionen

  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
  • UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • Henry Ford Cancer Institute, Detroit, MI 48202, USA.
  • Northwell Health Cancer Institute, New Hyde Park, NY 11040, USA.
  • Universty of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA.
  • Galera Therapeutics, Inc., Malvern, PA 19355, USA.

ORCID-Profile: Sarah E Hoffe

Förderung

  • Galera Therapeutics, Inc.

Zitieren

APA

Hoffe, S. E., Aguilera, T. A., Parikh, P. J., Ghaly, M. M., Herman, J. M., Caster, J. M., Kim, D. W., Costello, J., Malafa, M. P., Moser, E. C., Kennedy, E. P., Terry, K., & Kurman, M. (2024). Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design. Future Oncology. https://doi.org/10.2217/fon-2022-1219

Vancouver

Hoffe SE, Aguilera TA, Parikh PJ, Ghaly MM, Herman JM, Caster JM, et al. Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design. Future Oncology. 2024. doi:10.2217/fon-2022-1219

BibTeX
@article{Hoffe2024,
  author = {Hoffe, Sarah E and Aguilera, Todd A and Parikh, Parag J and Ghaly, Maged M and Herman, Joseph M and Caster, Joseph M and Kim, Dae Won and Costello, James and Malafa, Mokenge P and Moser, Elizabeth C and Kennedy, Eugene P and Terry, Kara and Kurman, Michael},
  title = {Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2022-1219}
}
Kostenlos starten →